04-13 Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL (news.google.com)
04-13 How Merck turned its wonder drug into a blockbuster — and priced out cancer patients worldwide - International Consortium of Investigative Journalists (news.google.com)
04-12 Legendary investor says the AI boom masks a deeper crisis: Falling sperm counts, shrinking populations, and vanishing resources (news.google.com)
04-11 The ''affordability economy'' has created a housing market nobody predicted: Prices collapsing in the Sun Belt, soaring in the Rust Belt (news.google.com)